blood investigations showed hemoglobin was 10.0 g/dl, total leukocyte count was 8100 cells/mm 3 , platelets were 364 × 10 3 cells/mm 3 , serum albumin was 2.4 g/dl, and total proteins were 11.6 mg/dl, AST 66 IU/L, ALT 304 IU/L, and ALP 72 IU/L. Rest of the investigations were within normal limits. Computerized tomography (CT) of the thorax revealed large (12.1 cm × 8.9 cm × 5 cm) heterogeneous mass involving left lateral chest wall with focal erosion of lateral aspect of 4 th rib. Radiating strands of bony spicules were noted arising from outer cortex of lateral aspect of 4 th rib. Diffuse rind-like heterogeneously enhancing irregular pleural thickening with moderate loculated left pleural effusion was also seen [ Figure 1b ]. Pleural fluid was hemorrhagic, exudative, lymphocyte predominant with ADA-49 U/L, and smear and culture for mycobacterium tuberculosis were negative. Pleural fluid cytology revealed proliferation of plasma cells with eccentric nuclei, perinuclear halo, and abundant amount of basophilic cytoplasm in a hemorrhagic background. A few binucleate forms were also seen (suggestive of plasmacytosis) [ Figure 2 ].
On bronchoscopic evaluation, there was extra-luminal compression in the left side with no endobronchial growth. An intercostal drainage tube was inserted in view of increasing dyspnea and rapid refilling of pleural fluid. Thoracoscopic-guided pleural biopsy was done for confirmation of diagnosis. During thoracoscopy, thickened nonsmooth parietal pleura studded with multiple reddish nodules were found. There were dense pleura-parenchymal adhesions with red membranous glistening surface of the pleura. Pleural biopsies were taken from pleural nodules [ Figure 3 ].
Histopathology report revealed nodular aggregates and sheets of atypical plasma cells with high nuclear-cytoplasmic ratio, eccentric nuclei, and abundant amount of eosinophilic cytoplasm, suggestive of plasmacytoma [ Figure 4 ]. In view of malignant myelomatous pleural effusion, pleurodesis was done, and since it was a recurrence of multiple myeloma, second-line drugs were started.
Case 2
A 58-year-old male was diagnosed with multiple myeloma in October 2016. The chemotherapy regimen given was bortezomib, thalidomide, and dexamethasone. He was doing well in the follow-up till November 2017, when he developed shortness of breath for 2 weeks, orthopnea for 3 days, cough, and hemoptysis for 2 weeks and stridor for 2 days. There was no history of fever, chest pain, or weight loss. On examination, the patient was found to be tachypneic and was using accessory muscles of respiration. He was afebrile with a pulse rate of 118/min, blood pressure 120/78 mmHg, respiratory rate 36/min, and oxygen saturation of 97% on 4 L/min of oxygen. On examination of the chest, breath sounds were decreased on the right side. Figure 5 ]. On videobronchoscopic examination, a mass was seen arising from the right main bronchus and obstructing the distal trachea [ Figure 6 ]. In view of central airway obstruction and stridor, urgent rigid bronchoscopy was done under general anesthesia. Coring of mass was performed, and a silicone Y-stent of size 16 was placed and distal segments identified. Post procedure, symptoms of breathlessness and stridor decreased. Histopathological examination (HPE) showed a tumor comprising of sheets of atypical plasma cells having eccentric-placed nuclei, coarse chromatin, occasional prominent nucleoli, and abundant amount of eosinophilic cytoplasm [ Figure 7 ]. Few binucleate and multinucleate forms were also seen. Features were suggestive of plasmacytoma. The patient was started on second-line drugs for multiple myeloma.
Case 3
A 65-year-old male was diagnosed multiple myeloma in January 2017. He presented to us with weight loss, decreased appetite, and dry cough for 2 months. The patient had no previous history of pulmonary tuberculosis, diabetes, and hypertension. On examination, the patient was afebrile with pulse rate of 98 beats/min, blood pressure of 110/80 mmHg, respiratory rate 20 beats/min, and oxygen saturation 98% on room air. On auscultation of the chest, crepitations were present on the left side. Laboratory investigations showed hemoglobin of 10.3 g/dl, total leukocyte count 9000 cells/mm 3 , platelets 154 × 10 3 cells/mm 3 , serum albumin 2.5 g/dl, and total proteins 11.0 mg/dl. Liver and kidney function tests were normal. Chest radiograph showed left-sided irregular opacities in lower zone. CECT thorax showed left-sided pleural-based heterogeneous mass with consolidation and rib erosion [ Figure 8 ]. Videobronchoscopy was done and no endobronchial abnormalities were detected. Bronchoalveolar lavage (BAL) sample was taken from left lower lobe. BAL Gene Xpert was positive for mycobacterium tuberculosis and rifampin sensitive. Cytopathology for malignant cells was negative. To confirm the diagnosis, CT-guided biopsy was done. HPE showed largely necrotic tissue with multiple granulomas composed of epitheloid histiocytes, lymphocytes, and multinucleated giant cell. Stain for acid-fast staining was negative [ Figure 9 ]. Antitubercular treatment (HRZE) was initiated, and he was doing well at follow-up.
dIscussIon
Multiple myeloma is a neoplastic disorder caused by the proliferation of monoclonal plasma cells and associated with production of large amount of monoclonal immunoglobulins. The classical thoracic manifestation of the disease is involvement of bone of the thoracic cage. Other pulmonary manifestations include consolidation, lung mass, mediastinal lymphadenopathy, interstitial involvement such as reticulonodular pattern and intrapulmonary calcification. In lower airways, plasmacytoma is mainly found in the tracheobronchial tree, hilar structures, and rarely in the lung parenchyma. [6, 7] In a study of 13 patients of multiple myeloma with different thoracic manifestations, six had consolidation, two had mass lesions, two had multiple nodular lesions, and three had interstitial infiltrates. [8] Pleural effusion is very rare, occurs in <1% and <100 cases have been reported. [9] The pleural effusion develops at an average of 12 months after the diagnosis. [2, 3, 10] Table 1 lists different thoracic radiology of multiple myeloma seen in different studies. [2, 3, [11] [12] [13] [14] Myelomatous pleural effusion is diagnosed by (a) pleural fluid electrophoresis demonstrating monoclonal protein, (b) demonstration of plasma cell in pleural fluid and (c) histological evidence in pleural biopsy. [15] In our case, we found plasma cells in pleural fluid and histopathology of parietal pleura was suggestive of myelomatous origin.
Treatment for myelomatous pleural effusion is not well established. Various antimyeloma agents in combination with local treatment are targeted at pleural effusion, such as pleurodesis, high-dose chemotherapy with peripheral blood stem cell support, intrapleural administration of alpha-interferon, doxorubicin and bortezomib. [16] Thalidomide remains the first-line treatment in multiple myeloma. In various studies, extramedullary plasmacytoma has been found to be less responsive to thalidomide. [17, 18] Our patient had a relapse despite treatment [11] Ramnik et al. [3] Sullivan et al. [2] Koss et al. [12] Saha et al. [14] Weber et al. [13] Present series with thalidomide and dexamethasone. Pleural involvement in myeloma is associated with an aggressive course, with poor response to first-or second-line therapies used for myeloma treatment.
conclusIon
The incidence of myelomatous pleural effusion and endobronchial plasmacytoma is rare. Involvement of these structures often signifies a poor prognosis and follows an aggressive natural course. In these situations, rapid diagnosis and treatment with second-line drugs should be considered.
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